#label id < 50 x 109/L Detail < 0.5 x 109/L Detail 10 days Period > 10 x ULN Detail 11-15 days Period 1mg/kg/d Detail 24-48h Period 26 other countries around the world Area 2 or more units of packed Dosage 2 times daily Times 3 times daily Times 4000 UI once day, increased to 6000 UI once day for patients weighting more than 90 kg Dosage regimen 4 times daily Times 500mg twice per day for 10 days Dosage regimen 6-10 days Period 8.15 days Period 8 days Period above 50 year of age Age above 50 years Age above 50 years of age Age ACE-2 Gene ACE2 Gene ACE-2 receptors Gene ACE-2 receptors Target ACE2 Target ACE Gene ACE inhibitors Inhibitor across the globe Area activation of the prostanoid thromboxane A2 receptor Problem acute clinically overt bleeding Disease acute respiratory Disease acute respiratory distress syndrome Disease acute Severity Adenovirus Species administered intravenously Chemical administered subcutaneously Chemical admission to ICU Therapy A dysfunction Disease aged 60 years and older Age aged 65 years and older Age age range of 21 to 50 years Age ageusia Disease Alamandine Chemical Alamandine Target allergy Disease all provinces in China Area altered sense of smell Disease altered sensorium Disease Alzheimer Disease Alzheimer's Disease Alzheimer's disease Disease Alzheimer's patients with pets Problem angigenesis Disease Angiotensin 1-7 Chemical Angiotensin 1-7 Gene Angiotensin 1-7 Target Angiotensin 1-9 Chemical Angiotensin 1-9 Gene Angiotensin 1-9 Target Angiotensin A Biological Angiotensin A Target angiotensin-converting enzyme 2 Gene Angiotensin-Converting Enzyme 2 Gene angiotensin-converting enzyme-2 receptor Gene Angiotensin-Converting Enzyme Gene Angiotensin Gene Angiotensin I Gene Angiotensin II Gene Angiotensin III Chemical Angiotensin III Gene Angiotensin II receptor Gene Angiotensin II Target Angiotensin IV Chemical Angiotensin IV Gene Angiotensin IV Target Angiotensinogen Biological anosmia Disease antagonists of AT1R Inhibitor cerebral neurons Biological anti-clotting inhibitor agents Inhibitor anti-clotting inhibitor agents Therapy anti-hypertensive Effect anti-hypertrophic Effect anti-IL6 inhibitors Inhibitor Anti-IL6 inhibitors Inhibitor anti-inflammatory cytokines Biological anti-inflammatory Effect any other bleeding Disease arachidonic acid Chemical arachidonic acid products Biological ARDS Disease arrest Disease aspartate decarboxylase Biological Aspergillus Species association between BMI and COVID-19-related mortality Detail AST/ALT values Detail asymptomatic (mostly in young age range) at the time of diagnosis Problem AT1R Gene AT1R Inhibitor AT2R Gene AT2R Target AT4R Biological AT4R Target at days 11 and 12 Period at days 13 and 14 Period atherosclerosis Disease at least 18 years of age Age at least 3 days Period at the late stage of the disease Period autoimmune inflammation of the central nervous system Disease average recovery time =5.4 days Period average recovery time =7.6 days Period Average recovery time Period a wide range of antiviral effects Effect below 10 years of age Age below 20 years of age Age bleeding compromising hemodynamic Disease bleeding Disease blockers Inhibitor blocking its inductors including IL-1 Therapy block spike protein binding Result blood vessels Biological brain Biological brain tissue Biological Brescia-COVID Scale Severity Brescia- COVID Severity Brescia-COVID Severity Bronchial Asthma Disease Candida Species Candidate Drugs Target cardiac Biological cardioprotective Effect cardiovascular and renal complications of diabetes Disease cardiovascular Biological cardiovascular comorbidities Disease cardiovascular disease Disease cats Species cell aggregation Disease central nervous system Biological cerebrospinal fluid Biological chest pain Disease chloroquine Chemical chloroquine phosphate Chemical chloroquine phosphate tablet Chemical Chronic kidney disease Disease clinically relevant non-major bleeding Disease clinical manifestations of COVID-19 Condition clotting abnormalities Disease coagulopathy Disease combining IL6-inhibitors Therapy co morbid Condition co morbid conditions Condition co morbid disease Disease co morbidity Disease compartment syndrome Disease control the release of pro-inflammatory cytokines Effect COPD Disease Coronary artery disease Disease coronavirus-19 Species coronavirus infectious disease 2019 Disease corticoesteroids Biological corticosteroids Biological Corticosteroids Biological cough Disease counter-regulatory' RAS Biological Counter-regulatory RAS In the RAS pathway Biological Counter-regulatory 'Renin-Angiotensin' System Biological COVID-19 Diseases Disease COVID-19 disorders Disease COVID-19 Disorders Disease COVID-19 pneumonia Disease COVID-19 symptoms Disease crackles Disease C-reactive Protein Gene cribriform plate Biological critically ill Disease critically-ill Disease CRP, LDH, serum ferritin, lymphopenia, or d-dimer Detail cytokines Biological cytokines Chemical cytokine storm Disease damages Disease dangerous scenario Result d-dimer >1.0 mcg/ml Detail d-dimer Biological d-dimer Problem D-dimer Problem death of more than a hundred thousand people across the globe Effect deaths Disease Deaths Disease deceased Species decoy for the recognition and competitive binding to the spike (S) glycoprotein of SARS-CoV-2 Therapy decrease in lymphocytes Problem degradation products of fibrin Problem dementia Disease depressed level of consciousness Disease depression Disease derivatives Inhibitor dermatitis Disease diabete Disease diabetes Disease Diabetes Disease Diabetes mellitus Disease diarrhea Disease died Disease direct relation between the neurologic symptoms and COVID-19 Effect diseases Disease diverticulitis Disease dizziness Disease dramatic Severity earlier state Severity early age Age early Disease early recovery without effectively influencing the overall mortality Result ecosanoids Chemical effective treatment Therapy electron microscopy Equipment Elevated levels of blood IL-6 Problem endothelial cell-leukocyte adhesion Result endothelial dysfunction Disease England Area enoxaparin Chemical Enoxaparin Chemical exacerbates AD symptoms Result extended lockdown of patients Therapy face mask with reservoir Therapy fatal Disease fatigue Disease Females Sex fever Disease Fever Disease fibrinogen Gene fibrinogen Problem first few days of admission Period for 7 days Period formation of thrombi Disease from day 8 to day 10 Period gantenerumab Chemical glaucoma Disease Glial cells Target glycaemic control Therapy haematuria Disease haemoptysis Disease hazard ratio [HR] 2·23 [95% CI 1·50-3·30, p<0·0001] Detail hazard ratio [HR] Detail HbA1c Biological HCQ Chemical HCQ Therapy headache Disease heart Biological heart failure Disease hematemesis Disease hematological changes Result hemodynamic changes Disease heparan sulfate Chemical Heparan Sulfate Chemical heparin Chemical heparin lyases Inhibitor Herpes Virus e Cytomegalovirus Species high-dose Dosage high flow nasal cannula Therapy high risk Severity hospitalized Detail HR 1·22 [95% CI 1·15-1·30, p<0·0001] for 59-74 mmol/mol [7·6-8·9%] and 1·36 [1·24-1·50, p<0·0001] for 75-85 mmol/mol [9·0-9·9%] Detail HR of 2·33 (1·53-3·56, p<0·0001) Detail HR of 2·45 (95% CI 1·60-3·75, p<0·0001) Detail HR of Detail human Species humans Species hydroxychloroquine Chemical Hydroxychloroquine Chemical hyperactive immune reaction Biological hyperglycaemia Disease hyperinflammatory syndrome Disease hypersensitivity Disease hypertension Disease hyposmia Disease hypotension Disease hypothalamus Biological hypovitaminosis D Disease ICU admission Detail ICU admission Severity IL-1 Gene IL-1Ra Gene IL-1 receptor antagonist Gene IL-1 treatments Therapy IL-6 > 40 pg/mL Detail IL6-inhibitors Inhibitor immune-modulatory drugs Chemical immune monocytes Biological immune outcomes Biological immunohistochemistry Equipment immunosuppressive antibody therapy Therapy improve patient outcome Result improve the success rate of treatment Result in a day Period increased heart rate Result increased mortality rate Result increased protein permeability Detail independently Condition infected 1,5 million people Effect infected by SARS-CoV-2 Effect infection by pseudotyped virus and authentic SARS-CoV-2 virus Result infections Disease inflamed environment Biological inflammation Disease infusion rate of 18 UI/kg/hour Dosage regimen inhibition Effect inhibition of viral adhesion by exogenous heparin Therapy in initial three days Period initial bolus of 0,5 mg/kg Dosage regimen innate immune Biological innate immunity Biological interleukin 1 Gene interstitial pneumonia Disease intestine Biological intra-articular Disease intracranial Disease intramuscular Disease intramuscular hematoma Disease intraocular Disease intra-spinal Disease intravascular coagulopathy Disease intravenously Chemical In vitro Condition in vitro Condition Jaipur Area Jaipur City Area Jaipur, Rajasthan Area joints pain Disease kidney Biological lack of formation of IL-1 Effect lactation Detail large increase in neutrophils that adhere to the lung Problem larger than 25 cm2 Detail LDH Biological less attention to hand hygiene Problem leukocyte aggregation Disease leukocyte aggregations Result leukopenia Disease life-threatening Severity liver Biological LMHW Chemical LMWH Chemical Losartan Chemical Losartan Inhibitor loss of sense of Disease loss of sense of smell Disease low molecular weight heparin Chemical lung Biological lung heparan sulfate Inhibitor lungs Target lymphopenia Disease macrophage intervention Detail macrophages Biological male Sex Male sex Sex males Sex Manipulation of heparan sulfate Therapy Mas-related G protein-coupled receptor member D Gene MasR Gene MasR Target mean age of 35.42 years Age mechanical ventilation Therapy metabolic Result metalloproteinases Problem methylprednisolone and low molecular weight heparin Therapy methylprednisolone and unfractionated heparin Therapy methylprednisolone Chemical Methylprednisolone Chemical micro-thrombi Disease mild Severity moderate Severity modified to obtain aPTT Ratio in between the range of 1.5-2.0 Dosage regimen monocytes Biological morbidity Detail more than 16 days Period more than a hundred thousand Detail mortality Disease Mortality Disease movement restriction Therapy MRGD Gene MRGD Target multi organ failure Disease multiple co morbid conditions Condition multiple Severity myocardial infarction Disease natural candidate peptide drugs Target nearly three-fourth Detail neurologic symptoms Disease neuronal death Disease neurons Target neutropenia Disease neutrophils Biological new infections Disease new organ dysfunction Disease new organ dysfunction Result non-anticoagulant heparin Inhibitor non-endothelial cells Biological non-invasive mechanical ventilation Therapy non-white ethnicity Species not receive any treatment Therapy novel coronavirus pneumonia Disease novel coronavirus Species obesity Disease old age Age older age Age older family members Species Old k-chest Disease olfactory epithelium Biological once a day Times once daily Times On cells Condition ongoing infectious Severity organ dysfunction Disease organ lesions Disease other countries Area other proteolytic enzymes Problem other symptoms Disease over-exuberant cytokine release Problem over-reaction of RAS Problem pain abdomen Disease participants Species Participants Species PARTICIPANTS Species pathogenesis of Disease pathogen infection Disease Patients Species people Species pericardial Disease persons Species pets Species platelet aggregation Disease platelet Disease platelet vascular thrombogenicity Disease pneumonia Disease polymorphonuclear Biological polymorphonuclear leukocytes Biological pregnancy Detail preventing the fatal consequences Effect Prevention of or induction of TxA2 Therapy primary disease process Problem progressive Severity progressive worsening in at least two Problem pro-inflammatory Biological pro-inflammatory cytokine Biological prone to develop symptomatology complex Problem Prostaglandins Chemical pulmonary edema Disease pulmonary infiltrates Disease radiographic Equipment rales Disease rapid reduction of systemic blood pressure Result RAS Biological RAS blockers Chemical RAS-dependent disorders Disease RAS imbalance Problem RAS inhibitors Chemical RAS inhibitors Inhibitor RAS over-reacted Problem real-time reverse transcription- PCR Equipment receptor-binding domain Target Recombinant ACE2 Therapy recombinant Detail red blood cells Biological reduced vascular resistance Result renal Biological renal impairment Disease renal tubules Biological Renin-Angiotensin-Aldosterone' system Biological Renin-Angiotensin' system Biological Renin-Angiotensin' System Biological Renin Biological requires supplemental oxygen Detail rescue administration of high-dose steroids or immune-modulatory drugs Dosage regimen resistance of systemic blood pressure Disease respiratory dysfunction Disease respiratory failure Disease respiratory injury Disease respiratory symptoms Disease Reverse Transcriptase Polymerase Chain Reaction Equipment RT-PCR Equipment sarilumab Chemical Sarilumab Chemical sarilumab + methylprednisolone plus SOC for COVID-19 Therapy sarilumab plus SOC Therapy SARS-CoV-2-infected Disease SARS-CoV-2 infection Disease SARS-CoV-2 Infection Disease SARS-CoV-2-related COVID-19 Disease SARS-CoV-2-related COVID-19 symptoms Disease seizure Disease sepsis Disease septic shock Disease seriously ill and hospitalized in intensive care Severity serum ferritin Biological Severe acute respiratory syndrome coronavirus 2 Species severe acute respiratory syndrome coronavirus Species severe Severity shock syndrome Disease shorten hospital stay Result shortness of breath Disease significantly Severity skin lesions Disease social distancing Therapy social isolation Problem socioeconomic deprivation Detail sodium enoxaparin Chemical solanezumab Chemical sore throat Disease Spain Area spike Gene SpO2 ≤ 94% Detail spontaneous hematoma Disease spontaneous rectal bleeding Disease standard prophylactic dosage Dosage regimen standard prophylactic dose Dosage regimen steroid Chemical steroids Chemical stroke Disease study drugs Chemical surface of epithelial cells Biological surgical intervention Therapy Symptomatic clinical manifestations Detail symptomatic Condition symptomatic Disease Symptomatic presentation of COVID-19 Condition systemic inflammation Disease systemic Severity tablet Chemical target RAS using specific candidate chemotherapeutic drugs Therapy taste Disease T-cells Biological temporary cessation of a study drug Disease testicle Biological therapeutic dosages Dosage regimen therapeutic doses Dosage regimen the release of Problem the release of pro-inflammatory cytokines Problem third to fifth decades of life Age This dysfunction Disease throboxane-A2 Chemical thrombi formation Disease thrombocytopenia Disease thrombogenesis Disease thrombosis Disease thrombotic complications Disease thrombotic diseases Disease thromboxane A2 Chemical thromboxane A2 receptor Gene thromboxane B2 Chemical thromboxane B2 release Result thromboxane B2 (TxB2) releases Result thromboxane Chemical Time of recovery Period TNF Gene transfusion of 2 or more units of packed red blood cells in a day Therapy twice per day Times two third Detail TxA2 Chemical TxA2 increases significantly Condition TxB2 Chemical TxB2 production Result type 1 diabetes Disease type 2 diabetes Disease UFH Chemical unfractionated heparin Chemical Unfractionated heparin Inhibitor up to ICU discharge Period U-shaped Detail Valvular heart disease Disease vascular Biological vascular Detail vascular endothelial organs Biological vasoactive Effect venous thromboembolism Disease viral attachment Disease viral infection Disease viral infections Disease viral pneumonia Disease vitamin D Chemical vitamin D deficiency Disease with clotting abnormalities Disease with corticosteroids Therapy within 5 days Period within the past 5 months Period women Species Wuhan Area young adult age Age Young family members Species gloves MESH:D017575 goggles MESH:D005135 masks MESH:D008397 N95 respirator MESH:D000087162 surgical Glove MESH:D005932 surgical gowns MESH:D058257